rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Approximately 75% of the cases were cytologically diagnosed as being positive for malignancy and these cases were associated with both the classic and tall cell variants of PTC at the time of resection, a greater likelihood of extrathyroidal extension, and the V600E type of BRAF mutation.
|
22887810 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.
|
30219154 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer.
|
24717435 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E)-mutated DNA was quantified in plasma samples and in cancer sections by quantitative real-time polymerase chain reaction (qPCR).
|
24858900 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Braf(V600E)-driven tumors require autophagy and likely autophagy-provided substrates to maintain mitochondrial metabolism and to promote tumor growth, suggesting that autophagy ablation may improve cancer therapy.
|
24860158 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds.
|
23343956 |
2013 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among nodules read as "suspicious for malignancy" on cytology.
|
26187369 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of BRAF(V600E) mutation had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy in subset of suspicious for malignancy FNABs.
|
21948220 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
|
25353071 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.
|
12068308 |
2002 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene.
|
16266992 |
2005 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, this IHC detection is sensitive for clinic uses as a simple, fast, inexpensive, and reliable method to screen cancer patients for the BRAF(V600E) mutation and could be easily adapted for use in most hospital pathology laboratories.
|
24563339 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in Braf(V600E) mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas.
|
25848750 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, we show that SkE, a very potent inhibitor of B-Raf-V600E, is highly effective against cancer cell lines that exhibit constitutive activation of the ERK1/2 pathway.
|
23518796 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy.
|
27818286 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In serrated adenomas, BRAF-V600E mutation does not seem to be associated with age and sex, with the prevalence of dysplasia and cancer and with the morphology of the dysplastic component.
|
30815911 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Interesting, Prof. Peng Hou and colleagues, at the First Affiliated Hospital of Xi'an Jiaotong University in China, identified unknown epigenetic mechanisms and their involvement in the tumorigenesis of B-RAF(V600E)-driven cancer.
|
28638488 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, 129 (92.1%) of the 140 malignant, and one (10%) of the 10 suspicious for follicular neoplasm cases showed BRAF(V600E) mutation.
|
21239517 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |